A randomized, controlled trial in children to assess the immunogenicity and safety of a thimerosal-free trivalent seasonal influenza vaccine

Pediatric Infectious Disease Journal

Volumn 31, Issue 6, 2012, Pages 605-615

  Domachowske, Joseph B ^a   Blatter, Mark ^b   Chandrasekaran, Vijayalakshmi ^c   Liu, Aixue ^c   Jain, Varsha K ^c   Fries, Louis ^c  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b Pediatric Alliance   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Adolescent; Children; Influenza vaccines; Thimerosal free

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE;

ADOLESCENT; ANOREXIA; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHILD; CHILDHOOD DISEASE; CHILL; CONTROLLED STUDY; CONVULSION; DROWSINESS; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEASONAL INFLUENZA; SEIZURE; SEROCONVERSION; SHIVERING; SIDE EFFECT; UNITED STATES;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; UNITED STATES; VACCINES, INACTIVATED;

EID: 84861531286     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31824e2924     Document Type: Article

References (20)

1. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet. 2003;362:1733-1745.
2. Neuzil KM, Mellen BG, Wright PF, et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000;342:225-231.
3. O'Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics. 2004;113(3 Pt 1):585-593.
4. Basta NE, Chao DL, Halloran ME, et al. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol. 2009;170:679-686.
5. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342:232-239.
6. Viboud C, Boëlle PY, Cauchemez S, et al. Risk factors of influenza transmission in households. Br J Gen Pract. 2004;54:684-689.
7. Fiore AE, Uyeki TM, Broder K, et al.; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1-62.
8. Offit PA, Jew RK. Addressing parents' concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics. 2003;112(6 Pt 1):1394-1397.
9. Agency for Toxic Substances and Disease Registry. Mercury public health statement. March 1999. Available at: http://www.atsdr.cdc.gov/ToxProfiles/tp46- c1-b.pdf.
10. Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics. 2001;107:1147-1154.
11. Gerber JS, Offit PA. Vaccines and autism: a tale of shifting hypotheses. Clin Infect Dis. 2009;48:456-461.
12. Global Advisory Committee on Vaccine Safety. Position of the Global Advisory Committee on Vaccine Safety regarding concerns raised by paper about the safety of thiomersal-containing vaccines. May, 2003. Available at: http://www.who.int/vaccine-safety/topics/thiomersal/statement/en/. Accessed February 17, 2011.
13. Global Advisory Committee on Vaccine Safety. Meeting of Global Advisory committee on Vaccine Safety, 18-19 June 2008. Wkly Epidemiol Rec. 2008;83:287-292.
14. Price CS, Thompson WW, Goodson B, et al. Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism. Pediatrics. 2010;126:656-664.
15. Committee on Infectious Diseases and Committee on Environmental Health. Thimerosal in vaccines-an interim report to clinicians. Pediatrics. 1999;104:570-574.
16. Fiore AE, Shay DK, Broder K, et al.; Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009;58(RR-8):1-52.
17. Food and Drug Administration. Thimerosal in vaccines. March 31, 2010. Available at: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ VaccineSafety/UCM096228. Accessed October 18, 2010.
18. Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. Food and Drug Administration (FDA). May 2007. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091990.pdf.
19. Baxter R, Jeanfreau R, Block SL, et al. A Phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. Pediatr Infect Dis J. 2010;29:924-930.
20. Centers for Disease Control and Prevention. CDC advisors make recommendations for use of vaccine against novel H1N1. July 29, 2009. Available at: http://www.cdc.gov/media/pressrel/2009/r090729b.htm. Accessed March 23, 2011.